# Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML

> **NCT00529880** · PHASE2 · UNKNOWN · sponsor: **Cooperative Study Group A for Hematology** · enrollment: 19 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Fludarabine , cytarabine

## Key facts

- **NCT ID:** NCT00529880
- **Lead sponsor:** Cooperative Study Group A for Hematology
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2007-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529880, "Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00529880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*